ExpreS2ion Biotechnologies – Update on EU-funded Nipah virus vaccine project
On 1 December 2023, ExpreS2ion Biotechnologies announced the award of a grant that amounts to EUR 8m (approx. SEK 90m) for the VICI-Disease consortium. 53% of the amount is a direct contribution to ExpreS2ion’s part of the project costs. The development project aims to obtain clinical proof-of-concept of a Nipah virus (NiV) vaccine candidate. This is the first strong signal of ExpreS2ion’s new strategy direction, leveraging the platform to advance assets with shorter development timelines and less costs to value creation.
ExpreS2ion Biotechnologies’ CEO Bent Frandsen will dig a bit deeper into the news about the Nipah virus vaccine project on 14 December 2023 at 10:00 in a virtual live event.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 15:03 8/12-2023.
